Filtered By:
Condition: Stroke
Vaccination: Vaccines
This page shows you your search results in order of date. This is page number 13.
Order by Relevance | Date
Total 855 results found since Jan 2013.
Why Pfizer Covid shot's stroke link as flagged by CDC and FDA is likely just a statistical anomaly
A preliminary link between Pfizer's Covid vaccine and an increased stroke risk in seniors over-65 cannot be stood up in further datasets, the CDC and FDA have said.
Source: the Mail online | Health - January 16, 2023 Category: Consumer Health News Source Type: news
CDC Says Stroke Concerns Over Pfizer Jab Warrant Investigation | ZeroHedge
CDC Says Stroke Concerns Over Pfizer Jab Warrant Investigation The Centers for Disease Control and Prevention (CDC) says that data collected on the Pfizer-BioNTech COVID-19 vaccine merits an investigation into potential stroke risks for people aged 65 and older. "Following the availability and use…#cathymcmorrisrodgers #fda #vsd #cdc #strokeconcerns
Source: Reuters: Health - January 15, 2023 Category: Consumer Health News Source Type: news
Pfizer Covid-19 Bivalent Vaccine And Stroke Risk: What You Need To Know
There ’s been a lot of chatter about the January 13 announcement from the Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA) about a possible “safety signal” for the Pfizer-BioNTech Covid-19 bivalent booster vaccine.
Source: Forbes.com Healthcare News - January 14, 2023 Category: Pharmaceuticals Authors: Bruce Y. Lee, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation Science /science business pharma Source Type: news
CDC, FDA Flag Early Signal of Stroke Risk With Bivalent COVID Vaccine
(MedPage Today) -- An early signal of stroke risk was detected in older adults who received Pfizer-BioNTech's bivalent COVID-19 vaccine, the FDA and CDC announced in a joint statement late on Friday, yet the agencies found no link in further analyses...
Source: MedPage Today Public Health - January 14, 2023 Category: American Health Source Type: news
No Increased Stroke Risk Linked to Pfizer ’s Covid Boosters, Federal Officials Say
An uptick hinted at in surveillance data was a mirage, the officials said.
Source: NYT Health - January 14, 2023 Category: Consumer Health News Authors: Apoorva Mandavilli Tags: your-feed-science Vaccination and Immunization Coronavirus (2019-nCoV) Elderly Stroke Coronavirus Risks and Safety Concerns BioNTech SE Pfizer Inc Centers for Disease Control and Prevention Food and Drug Administration Source Type: news
CDC identifies possible ' safety concern ' for certain people receiving COVID vaccines
The Centers for Disease Control and Prevention (CDC) says that a preliminary COVID-19 vaccine "safety signal" has been identified and is investigating whether the Bivalent Pfizer-BioNTech vaccine creates an increased risk of ischemic stroke in people 65 and older. In the Friday statement, the CDC…#pfizerbiontech #foxnewsdigital #omicron #cdc #vsd #marcsiegel #medicaidservices #fda #pfizer #medicare
Source: Reuters: Health - January 13, 2023 Category: Consumer Health News Source Type: news
A case of ischemic stroke and transient thrombocytopenia in a young female following adenoviral vector-based COVID-19 vaccination: Was the association incidental or causal?
We report a 23-year-old healthy female who developed seizures, altered sensorium, and left hemiparesis, 20 days after receiving the first dose of adenoviral vector-based COVID-19 vaccine "Covishield™." The patient had transient thrombocytopenia. The D-dimer level was 2460 ng/mL. Magnetic resonance imaging (MRI) demonstrated occlusion of M2 segment of the middle cerebral artery and cerebral infarction. Platelet factor-4 antibodies level was normal. Treatment with aspirin and antiepileptic drugs resulted in a remarkable recovery. This is the first Indian case report of ischemic stroke and transient thrombocytopenia followi...
Source: Primary Care - January 9, 2023 Category: Primary Care Authors: Shweta Pandey Ravindra Kumar Garg Pooja Tripathi Hardeep S Malhotra Neeraj Kumar Source Type: research
Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Risk of, and risk factors for, vasculopathy associated with acute herpes zoster
We aimed to summarize the known risk of vasculopathy (stroke, myocardial infarction [MI], and transient ischemic attack [TIA]) after herpes zoster (HZ) and the impact of antiviral treatment and vaccination against HZ on the risk of vasculopathy.
Source: Journal of Stroke and Cerebrovascular Diseases - December 3, 2022 Category: Neurology Authors: Barbara P. Yawn, Alistair C. Lindsay, Mitra Yousefi, Chengbin Wang Source Type: research
Neurological Complications and Consequences of the Novel Coronavirus COVID-19 Infection in Elderly and Senile Patients (Literature Review)
AbstractBased on available publications, the article systematizes information about some forms of lesions of the central nervous system (CNS), their pathogenesis and clinical manifestations in the case of COVID-19. The risk factors, mechanisms of development, diagnostic approach, and the age characteristics of patients with neurological complications of COVID-19 are discussed. The specific mechanisms of the neuroinvasiveness and neurovirulence of the SARS-CoV-2 virus, regardless of the age of patients and the presence of risk factors, lead to systemic damage to the endothelium of small-caliber vessels, generalized thrombov...
Source: Advances in Gerontology - December 1, 2022 Category: Geriatrics Source Type: research
Flu vaccine could slash the risk of stroke by 23% study suggests – how to get your jab
As well as protecting you from severe flu, the vaccine could also reduce your risk of death and disability.
Source: Daily Express - Health - November 29, 2022 Category: Consumer Health News Source Type: news
Is a high chest CT severity score a risk factor for an increased incidence of long-term neuroimaging findings after COVID-19?
From the outbreak of the Coronavirus disease 2019 (COVID-19) pandemic on 17 November 2019 in Wuhan to 2 November 2022, the total number of cases was reported as 617,879,854 and the total number of deaths was reported as 6,546,448 worldwide 1. In Turkey, the first case was reported on March 11, 2020. Until November 2, 2022, the total number of cases was 16,873,793 and the total number of deaths was 101,139 1. Today, there is a significant decrease in the number of cases and deaths as a result of vaccination and mutations in the virus.
Source: Journal of Stroke and Cerebrovascular Diseases - November 29, 2022 Category: Neurology Authors: Ahmet-Turan Kaya, Burcu Akman Source Type: research
Brain perfusion single photon emission computed tomography abnormality in MRI-negative stroke-like patients post COVID-19 vaccination
Stroke-like symptoms after COVID-19 vaccination was thought to be functional if there was no anatomical image abnormality. We aimed to analyze brain perfusion changes in these patients. A case-control study of brain perfusion single photon emission computed tomography (SPECT) of 12 vaccinated patients with left-sided stroke-like symptoms were compared with 12 age- and gender-matched normal interictal brain SPECTs using voxel-based analysis. Significant hyperperfusion was seen on the right side in postcentral, inferior parietal, mid temporal, parahippocampal, and caudate regions, and on the left side in the thalamus, hippoc...
Source: Medicine - November 25, 2022 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019-2020
CONCLUSION: AESI background rates varied by database and demographics and fluctuated in March-December 2020, but most returned to pre-pandemic levels after May 2020. It is critical to standardize demographics and consider seasonal and other trends when comparing historical rates with post-vaccination AESI rates in the same database to evaluate COVID-19 vaccine safety.PMID:36404170 | DOI:10.1016/j.vaccine.2022.11.003
Source: Vaccine - November 20, 2022 Category: Allergy & Immunology Authors: Keran Moll Bradley Lufkin Kathryn R Fingar Cindy Ke Zhou Ellen Tworkoski Chianti Shi Shayan Hobbi Mao Hu Minya Sheng Jillian McCarty Shanlai Shangguan Timothy Burrell Yoganand Chillarige Jeff Beers Patrick Saunders-Hastings Stella Muthuri Kathryn Edwards Source Type: research
Vaccine associated benign headache and cutaneous hemorrhage after ChAdOx1 nCoV-19 vaccine: A cohort study
Fatal complications have occurred after vaccination with ChAdOx1 nCoV-19, a vaccine against Covid-19. Vaccine-induced immune thrombotic thrombocytopenia (VITT) with severe outcome is characterized by venous thrombosis, predominantly in cerebral veins, thrombocytopenia and anti-PF4/polyanion antibodies. Prolonged headaches and cutaneous hemorrhages, frequently observed after the ChAdOx1 nCoV-19 vaccine, have therefore caused anxiety among vaccinees. We investigated whether these symptoms represent a mild form of VITT, with a potential for aggravation, e.g.
Source: Journal of Stroke and Cerebrovascular Diseases - November 17, 2022 Category: Neurology Authors: Nina Haagenrud Schultz, Arne Vasli Lund S øraas, Ingvild Hausberg Sørvoll, Çigdem Akalin Akkök, Annette Vetlesen, Jagjit Singh Bhamra, Maria Therese Ahlen, Pål Andre Holme, Anne-Hege Aamodt, Karolina Skagen, Thor Håkon Skattør, Mona Skjelland, Mark Source Type: research
